These rules are part of the Medicare Secondary Payer program, designed to help Medicare determine when it should not be the primary payer of claims. The Benefits Coordination & Recovery Center and ...
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full ...
The Social Security Administration (SSA) has begun issuing payments under the Social Security Fairness Act, which eliminates ...
The unknown of the German vote with its repercussions on the already shaky EU worries the financial markets. Only Piazza ...
If you enroll in a Part D or Medicare Advantage plan for 2025, you won’t have to pay more than $2,000 in out-of-pocket costs ...
The excess payments Medicare Advantage plans receive for higher risk scores may be more influenced by differences in coding practices rather than actual differences in disease burden between MA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback